Abstracts tagged "interleukins (IL)"

Abstract Number: 200 • 2015 ACR/ARHP Annual Meeting
Mast Cell Regulation of Aortic IL-6 Expression Involves Histamine-1 Receptor, Suppressor of Cyotkine Signaling-1 and IL-10
Vineesh Raveendran¹, Jason Springer², Donald Smith³, Mehrdad Maz⁴ and Kottarappat Dileepan¹, ¹Department of Medicine, University of Kansas Medical Center, Kansas City, KS, ²Division of Allergy, Clinical Immunology and Rheumatology, University of Kansas Medical Center, Kansas City, KS, ³University of Kansas Medical Center, Kansas City, KS, ⁴Division of Rheumatology, University of Kansas Medical Center, Kansas City, KS
Background/Purpose: IL-6 plays an important role in the pathogenesis of large vessel vasculitis. Lipopolysaccharide (LPS), acting through toll-like receptor 4, enhances both the aortic expression…
Abstract Number: 3039 • 2015 ACR/ARHP Annual Meeting
Possible Contribution of HLA-A0207, B5201 and IL-23 Receptor Polymorphism in Ocular Behçet Disease
Toshikatsu Kaburaki¹, Shinji Harihara², Rie Tanaka³, Hiromasa Sawamura⁴, Ai Nishi⁴, Atsushi Hatamochi⁵, Jun Shimizu⁶, Masumi Takeuchi⁷, Shoji Kuwata⁸, Hidetoshi Kawashima⁹ and Fujio Takeuchi¹⁰, ¹Ophthalmology, The University of Tokyo Graduate School of Medicine, Tokyo, Japan, ²Division of Anthropology, Department of Biological Science, The University of Tokyo Graduate School of Science, Tokyo, Japan, ³Department of Ophtalmology, The University of Tokyo Graduate School of Medicine,, Tokyo, Japan, ⁴Department of Ophtalmology, The University of Tokyo Graduate School of Medicine, Tokyo, Japan, ⁵Department of Dermatology, Dokkyo Medical University, Tochigi, Japan, ⁶Department of Neurology, The University of Tokyo Graduate School of Medicine, Tokyo, Japan, ⁷Teikyo University Support Center for Women Physicians and Researchers, Teikyo University School of Medicine, Tokyo, Japan, ⁸Third Department of Internal Medicine, Teikyo University Chiba Medical Center, Teikyo University School of Medicine, Chiba, Japan, ⁹Department of Ophthalmology, Jichi Medical University, Tochigi, Japan, ¹⁰Department of Allergy and Rheumatology, The University of Tokyo Graduate School of Medicine, Tokyo, Japan
Background/Purpose: Behçet's disease (BD) is known to be associated with HLA-B*51:01 and HLA- A*26:01 in many different ethnic groups. Recently, HLA-A*02:07, IL-10 and IL23R-IL12RB polymorphisms…
Abstract Number: 593 • 2015 ACR/ARHP Annual Meeting
Predicting the Need for Additional Treatment in Early Rheumatoid Arthritis Patients Treated to Target on Methotrexate Monotherapy
Xavier Teitsma¹, Johannes Jacobs², Paco Welsing³, Thasia Woodworth⁴, Attila Pethö-Schramm⁵, Michelle Borm⁶, Corrado Bernasconi⁵, Floris Lafeber¹ and Johannes W J Bijlsma⁷, ¹Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ²Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ³Department Rheumatology and clinical immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁴Medicine, Division of Rheumatology, David Geffen School of Medicine, Los Angeles, CA, ⁵F. Hoffmann-La Roche, Basel, Switzerland, ⁶Beneluxlaan 2a, Roche Nederland BV, Woerden, Netherlands, ⁷Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: Joint damage and functional disability can be reduced by intensive treatment of newly diagnosed rheumatoid arthritis (RA) patients during the "window of opportunity". Although…
Abstract Number: 3221 • 2015 ACR/ARHP Annual Meeting
Safety and Efficiency of Low-Dose Interleukin-2 Treatment in Systemic Lupus Erythematosus
Jing He¹, Xia Zhang², Yunbo Wei³, Xiaolin Sun⁴, Jianping Guo⁵, Yuebo JIn⁶, Rulin Jia⁶, Lei Zhu⁶, Zhaohua Hou⁷, Yaping Chen⁸, Yuan An⁶, Yuan Jia⁶, Xu Liu⁶, Limin Ren⁶, Ru Li⁶, HUA YE⁹, Shi Chen⁶, Xuewu Zhang¹⁰, Yin Su¹¹, Eric Morand¹², Yu Di¹³ and Zhanguo Li⁶, ¹Peking Univerisity People's Hospital, Beijing, China, ²Department of Rheumatology & immunology, Peking University People's Hospital, Beijing, China, ³Immunology for Environment and Health, Shandong Analysis and Test Center, Shandong Academy of Science, Shandong, China, ⁴People's hospital,Peking University, Beijing, China, ⁵Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China, ⁶Peking University People's Hospital, Beijing, China, ⁷Shandong Analysis and Test Center, Beijing, China, ⁸Monash University, Clayton, Austria, ⁹No.11 XIZHIMENG SOUTH STREET,, Peking University People's Hospital, Beijing, China, ¹⁰Rheumatology, Peking University People's Hospital, Beijing, China, ¹¹Department of Rheumatology and Immunology,Clinical Immunology Center, Peking University People's Hospital, Beijing, China, ¹²Medicine, Monash University, Clayton, Australia, ¹³Molecular Immunomodulation Laboratory, Monash University, Clayton, Austria
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with multi-system involvement, associated with an imbalance between effector and regulatory CD4+ T cells. The…
Abstract Number: 967 • 2015 ACR/ARHP Annual Meeting
Safety, Tolerability, and Pharmacodynamics of ABT-122, a Dual TNF- and IL-17-Targeted Dual Variable Domain (DVD)-IgTM in Subjects with Rheumatoid Arthritis
Roy Fleischmann¹, Frank Wagner², Alan J. Kivitz³, Heikki T. Mansikka⁴, Nasser Khan⁴, Jia Liu⁴, Jacob Gagnon⁴, Feng Hong⁵, Melanie Ruzek⁴ and Robert J. Padley⁴, ¹University of Texas Southwestern Medical Center at Dallas, Dallas, TX, ²Charité Research Organisation GmbH, Berlin, Germany, ³Altoona Center for Clinical Research, Duncansville, PA, ⁴AbbVie Inc., North Chicago, IL, ⁵AbbVie Inc., Worcester, MA
Background/Purpose: TNF and IL-17 independently contribute to the pathophysiology of rheumatoid arthritis (RA) acting synergistically to induce mediators of inflammation and joint destruction. Selective dual…
Abstract Number: 1511 • 2014 ACR/ARHP Annual Meeting
COVA322: A Clinical Stage Bispecific TNF/IL-17A Inhibitor for the Treatment of Inflammatory Diseases
Wibke Lembke, Bernd Schlereth, Julian Bertschinger, Dragan Grabulovski and Mathias Locher, Covagen AG, Schlieren, Switzerland
Background/Purpose: Biologic therapeutics such as TNF inhibitors have revolutionized the treatment of inflammatory diseases, including rheumatoid arthritis (RA), psoriasis and psoriatic arthritis. However, there is still…
Abstract Number: 1491 • 2014 ACR/ARHP Annual Meeting
Discovery and Characterization of COVA322, a Clinical Stage Bispecific TNF/IL-17A Inhibitor for the Treatment of Inflammatory Diseases
Dragan Grabulovski, Michela Silacci, Wibke Lembke, Wenjuan Zha, Richard Woods, Roger Santimaria, Julian Bertschinger and Mathias Locher, Covagen AG, Schlieren, Switzerland
Background/Purpose: Biologics such as TNF inhibitors have revolutionized the treatment of inflammatory diseases including rheumatoid arthritis (RA), psoriasis and psoriatic arthritis. However, recent data suggest that…
Abstract Number: 1492 • 2014 ACR/ARHP Annual Meeting
Safety and Tolerability of NNC01140006, an Anti-IL-21 Monoclonal Antibody, at Multiple s.c. Dose Levels in Patients with Rheumatoid Arthritis
Frank Wagner¹, Birte Skrumsager² and Sergey Fitilev³, ¹Charité Research Org GmbH, Berlin, Germany, ²Novo Nordisk A/S, Søborg, Denmark, ³Department of Clinical Pharmacology, Municipal Clinic #2, Moscow, Russia
Background/Purpose A phase 1, randomised, double-blind, placebo-controlled, dose-escalation trial was conducted to assess the safety and tolerability of the anti-IL-21-antibody NNC0114-0006, in patients with active…
Abstract Number: 1459 • 2014 ACR/ARHP Annual Meeting
IL-22 Secreted By NKp44+NK Cells Promote the Proliferation of Synovium in Patients with Rheumatoid Arthritis By Activation of STAT3
Junqing Zhu¹, Juan Li¹ and Xiaoguang Chen², ¹Nanfang Hospital, College of Traditional Chinese Medicine, Southern Medical University, Guangzhou, China, ²School of Public Health and Tropical Medicine, Southern Medical University, Guangzhou, China
Background/Purpose: Although CD3-CD56+NKp44+ natural Killer cells (NKp44+NK cells) have been linked to autoimmune diseases including inflammatory bowel disease, ankylosing spondylitis, and primary Sjogren's syndrome, the…
Abstract Number: 1253 • 2014 ACR/ARHP Annual Meeting
Anakinra – a Promising New Therapy for Idiopathic Recurrent Pericarditis
Sonia Jain¹, Charat Thongprayoon², Raul Espinosa¹, Sharonne Hayes¹, Kyle Klarich¹, Kevin Moder³, Nandan Anavekar¹, Jae Oh¹ and Eric L. Matteson⁴, ¹Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, ²Department of Medicine, Mayo clinic, Rochester, MN, ³Division of Rheumatology, Mayo Clinic, Rochester, MN, ⁴Rheumatology, Mayo Clinic, Rochester, MN
Background/Purpose Idiopathic recurrent pericarditis (IRP) is a debilitating condition that can be recalcitrant to conventional therapy. Some patients develop steroid dependency with the attendant risks…
Abstract Number: 1030 • 2014 ACR/ARHP Annual Meeting
ABT-122, a Novel Dual Variable Domain (DVD)-Ig^TM, Targeting TNF and IL-17, Inhibits Peripheral Blood Mononuclear Cell Production of GM-CSF and Decreases Lymphocyte Expression of CXCR4 in Healthy Subjects
Melanie Ruzek¹, Donna Conlon¹, Heikki Mansikka², Robert Padley² and Carolyn Cuff³, ¹AbbVie, Inc, Worcester, MA, ²AbbVie, Inc, North Chicago, IL, ³Immunology, AbbVie, Inc, Worcester, MA
Background/Purpose: TNF and IL-17 contribute to the pathogenesis of several inflammatory disorders and are known to synergistically induce chemokines and cytokines, including chemokine (C-X-C motif)…
Abstract Number: 998 • 2014 ACR/ARHP Annual Meeting
β2 Adrenoceptor Signal Is Augmented in B Cells in the Course of Arthritis to Increase IL-10
Georg Pongratz¹, Clemens Wiest², Madlen Melzer² and Rainer Straub³, ¹Internal Medicine I, University Hospital Regensburg, Regensburg, Germany, ²University Hospital Regensburg, Regensburg, Germany, ³Internal Medicine, University Hospital Regensburg, Regensburg, Germany
Background/Purpose Splenic B cells from collagen-induced arthritis (CIA) mice react to a β2-adrenoceptor (AR) stimulus with increased IL-10 production and adoptive transfer of these cells…
Abstract Number: 951 • 2014 ACR/ARHP Annual Meeting
Safety, Tolerability, and Functional Activity of ABT-122, a Dual TNF- and IL-17A–Targeted DVD-Ig™, Following Single-Dose Administration in Healthy Subjects
Heikki Mansikka¹, Melanie Ruzek², Margaret Hugunin², Alexander Ivanov², Alyssa Brito², Anca Clabbers², Carolyn Cuff³, Chung-Ming Hsieh², Martin Okun¹, Renee Heuser¹, David Carter¹, Barbara Hendrickson¹, Dipak Pisal¹, Sandra Goss¹, Jia Liu¹, Charles Locke¹, Nasser Khan¹ and Robert Padley¹, ¹AbbVie, Inc, North Chicago, IL, ²AbbVie, Inc, Worcester, MA, ³Immunology, AbbVie, Inc, Worcester, MA
Background/Purpose: Several lines of evidence indicate that greater clinical efficacy and protection of joints may be possible in patients with RA by neutralizing TNF and…
Abstract Number: 2876 • 2014 ACR/ARHP Annual Meeting
Interleukin-10 Receptor Blockade during Lcmv Infection Results in Macrophage Activation Syndrome-like Disease in Mice
Lehn K. Weaver¹ and Edward M. Behrens², ¹Pediatric Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA, ²Pediatric Rheumatology, Childrens Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: Macrophage activation syndrome (MAS) is the rheumatic disease-associated member of a group of hyperinflammatory syndromes characterized by uncontrolled cytokine storm manifest as unremitting fevers,…
Abstract Number: 947 • 2014 ACR/ARHP Annual Meeting
Efficacy and Safety of NNC01140006, an Anti-IL-21 Monoclonal Antibody, in Patients with Active Rheumatoid Arthritis
Juan D. Cañete¹, Piotr Leszczynski², Rikke Riisbro³ and Klaus S. Frederiksen³, ¹Arthritis Unit. Rheumatology Department, Hospital Clínic of Barcelona, Barcelona, Spain, ²Department of Rheumatology and Rehabilitation, Poznan Medical University, Poznan, Poland, ³Novo Nordisk A/S, Søborg, Denmark
Background/Purpose A phase 2, randomised, double-blind, placebo-controlled, parallel-group trial was conducted to evaluate the efficacy and safety of NNC0114-0006 in patients with active rheumatoid arthritis…

« Previous Page
1
…
5
6
7
8
9
…
12
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].